{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075944","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.620681+00:00","generated_at":"2026-05-17T15:59:19.765847+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theriva Biologics reports Q2 2025: VCN-01 Phase 2b success, cash $12.1M, runway into Q1 2026","bullets":["Positive topline from VIRAGE Phase 2b: VCN-01 plus chemo improved OS, PFS, DOR vs chemo alone in metastatic pancreatic cancer.","Cash and cash equivalents $12.1M as of June 30, 2025; early Aug cash $9.5M, expected runway into Q1 2026.","G&A expenses $11.2M (up 662% YoY) due to $9.2M contingent consideration adjustment from VIRAGE success; R&D $2.0M (down 34%).","Expanded VIRAGE data to be presented at ESMO 2025 Congress in October.","Phase 1 retinoblastoma data of VCN-01 presented at ASCO 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075944","json":"https://secwatch.observer/filing/0001104659-25-075944.json","markdown":"https://secwatch.observer/filing/0001104659-25-075944.md","text":"https://secwatch.observer/filing/0001104659-25-075944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/0001104659-25-075944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/tm2522967d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:59:19.765847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}